Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics.

Adopted guidelines reflect a harmonised European approach to a specific scientific issue and should reflect the most recent scientific knowledge. However, whilst EU regulations are mandatory for all member states and EU directives must be followed by national laws in line with the directive, EMA guidelines do not have legal force and alternative approaches may be taken, but these obviously require more justification. This new series of the BJCP, developed in collaboration with the EMA, aims to address this issue by providing an annotated version of some relevant EMA guidelines and regulatory documents by experts. Hopefully, this will help in promoting their diffusion and in opening a forum for discussion with our readers.

[1]  R. Portman,et al.  Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates , 2017, Pediatric Research.

[2]  D. Tibboel,et al.  A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span , 2012, Pharmaceutical Research.

[3]  P. Smith,et al.  Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration , 2019, JAMA pediatrics.

[4]  A. Saint‐Raymond,et al.  Paediatric extrapolation: A necessary paradigm shift , 2019, British journal of clinical pharmacology.

[5]  Nick Holford,et al.  A pharmacokinetic standard for babies and adults. , 2013, Journal of pharmaceutical sciences.

[6]  A. Needham,et al.  Pharmacokinetic studies in children: recommendations for practice and research , 2018, Archives of Disease in Childhood.

[7]  J. Momper,et al.  Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. , 2013, JAMA pediatrics.

[8]  J. Blumer.  Off-Label Use of Drugs in Children , 1999, Medications in Pediatrics.

[9]  M. Karlsson,et al.  The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop , 2013, CPT: pharmacometrics & systems pharmacology.

[10]  Armin Koch,et al.  How to use prior knowledge and still give new data a chance? , 2018, Pharmaceutical statistics.

[11]  D. Tibboel,et al.  Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade? , 2016, Clinical Pharmacokinetics.

[12]  J. Barrett,et al.  Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development , 2016, Journal of clinical pharmacology.

[13]  Bradley P Carlin,et al.  Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation , 2017, Pharmaceutical statistics.

[14]  D. Tibboel,et al.  Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments , 2018, CPT: pharmacometrics & systems pharmacology.

[15]  R. Ward,et al.  Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies , 2015, Paediatric anaesthesia.

[16]  K. Neville,et al.  Off-Label Use of Drugs in Children , 2014, Pediatrics.

[17]  Y. Böttiger,et al.  Paediatric drug use with focus on off-label prescriptions at Swedish hospitals – a nationwide study , 2012, Acta paediatrica.

[18]  S. Marshall,et al.  Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation , 2016, CPT: pharmacometrics & systems pharmacology.

[19]  W. Rodriguez,et al.  Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs , 2011, Pediatrics.

[20]  J. Barrett,et al.  Challenges and Opportunities in the Development of Medical Therapies for Pediatric Populations and the Role of Extrapolation , 2018, Clinical pharmacology and therapeutics.

[21]  P. H. van der Graaf,et al.  Children Are Not Small Adults, but Can We Treat Them As Such? , 2019, CPT: pharmacometrics & systems pharmacology.

[22]  Lisa V Hampson,et al.  Bayesian methods for the design and interpretation of clinical trials in very rare diseases , 2014, Statistics in medicine.

[23]  Martin Posch,et al.  Evidence, eminence and extrapolation , 2016, Statistics in medicine.

[24]  Aaron Sachs,et al.  Pediatric information in drug product labeling. , 2012, JAMA.

[25]  崎山美知代.  有効性に関するトピックの動向 ICH E11‐Addendum(R1):Clinical Investigation of Medicinal Products in the Pediatric Population Lisbon2016EWG会議の報告 , 2017 .